Yumeen et al. highlighted the potential roles of combination approaches using JAK, Bcl-2, bromodomain and extra-terminal domain (BET), and HDAC inhibition in advanced CTCL [62]. The gene discussed is BCL2; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.